Gibbs C J, Aaron J E, Peacock M
Br Med J (Clin Res Ed). 1986 May 10;292(6530):1227-9. doi: 10.1136/bmj.292.6530.1227.
Eleven patients with Paget's disease treated with sodium etidronate 20 mg/kg/day for two and four weeks showed significant reductions in plasma alkaline phosphatase activity and urinary hydroxyproline excretion, both of which are biochemical markers of bone turnover. After four weeks of treatment, however, histological examination of iliac crest biopsy samples showed that despite a rapid reduction in bone resorption there was an appreciable mineralisation defect; even after only two weeks' treatment the abnormalities in bone formation persisted for up to 10 weeks. The adverse effects of sodium etidronate on mineralisation cannot be dissociated from its beneficial effect on resorption even when it is given for short periods.
11例佩吉特病患者接受依替膦酸钠20mg/kg/天治疗2周和4周后,血浆碱性磷酸酶活性和尿羟脯氨酸排泄量均显著降低,这两者都是骨转换的生化指标。然而,治疗4周后,髂嵴活检样本的组织学检查显示,尽管骨吸收迅速减少,但仍存在明显的矿化缺陷;即使仅治疗2周,骨形成异常仍持续长达10周。即使短期使用依替膦酸钠,其对矿化的不良影响也与其对吸收的有益作用无法分开。